Business Wire

CHRYSO®Quad: A Range of Admixtures and Services for Complex Local Sands and Aggregates, in Support of the Circular Economy

20.4.2023 12:20:00 EEST | Business Wire | Press release

Share

To support sustainable construction stakeholders, CHRYSO is strengthening its CHRYSO®Quad range and associated services in response to the challenges of the circular economy. CHRYSO promotes the use of complex aggregates sourced locally or from recycled concrete from deconstruction sites.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230418005807/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

CHRYSO®Quad fosters local sourcing of aggregates and sands (Photo: Shutterstock)

Dedicated services to characterize materials and adjust admixture solutions

It all starts with the analysis of sands using the patented CHRYSO®CLEAR Test method, which diagnoses the presence of swelling clay. Then, the dedicated CHRYSO®Quad Lab service allows CHRYSO experts to carry out a precise diagnosis of a series of additional parameters: particle size (to determine the lack or excess of fines), absorption, shape factors, etc.

Additionally, compaction tests are performed in CHRYSO's application laboratories to consider all the parameters of the concrete mix design. Finally, the brand-new digitalized service CHRYSO®Quad App proposes the most suitable admixture solution based on the customer's material characterization (sands and aggregates) and thus broadens the scope of potential supply sources.

The use of complex aggregates and sands while improving concrete performance

The customized CHRYSO®Quad admixture solutions are adjusted according to the available resources of complex sands and aggregates. This allows clients to gain flexibility by integrating new sands and aggregates into their concrete mix and overcome shortages or tensions in material supplies. CHRYSO experts accompany their clients in producing durable and robust concrete that can withstand material variations.

CHRYSO®Quad contributes to the circular economy and reduces the carbon footprint

By anticipating the constraints of quality and availability of local sands and aggregates, CHRYSO®Quad fully embraces a circular economy approach.

CHRYSO®Quad is a development lever for recycling materials from deconstruction, allowing for the recovery and use of recycled aggregates.

The use of local resources also contributes to reducing supply costs and decreasing the carbon footprint associated with the transportation of raw materials.

CHRYSO continues to deploy CHRYSO®Quad

To date, 9 million m3 of concrete have already benefited from CHRYSO®Quad solutions, including on large construction sites around the world. Leveraging its international network of application laboratories, CHRYSO provides answers to the sourcing challenges of aggregates faced by industry stakeholders.

CASE STUDY

With CHRYSO®Quad 870, a concrete industry player manages to use 100% of complex sands in its concrete formulation

To support a client in the south of France in optimizing the sand resources used in its concrete formulation, CHRYSO proposed its CHRYSO®Quad 870 solution, which improved productivity, concrete quality, and allowed for sourcing exclusively from local suppliers.

This industry player supplied his plant with sand from two quarries. A complex crushed sand, sourced from a quarry near the plant. A second "corrective" sand, from another quarry located 60km from the plant. Up to 50% of each sand was used in the different concrete mixes, which ranged from class S3 to S5.

In its specifications, the industry player requested that CHRYSO provides a solution to increase its capacity to use complex sands (with a high content of fines and the presence of clays). Thanks to the CHRYSO®Quad Lab service, sands were recovered and analyzed in the laboratory and in the plants. This allowed CHRYSO to design the customized CHRYSO®Quad 870 product. The first product testing phases were validated on site by sand variability checks carried out by the client using the CHRYSO®CLEAR Test kit.

As a result, the customer has extended the use of CHRYSO®Quad 870 to three other concrete plants and now uses 100% complex sand from a local quarry. The use of a single sand, with a constant dosage, brings a benefit of regularity in the production, reducing the weight of CEM II A cement in the design mix, which represents a 10% reduction of the carbon footprint. In addition, thanks to the exclusive use of short-distance sourcing, 24 lorry journeys per month have been avoided.

ABOUT SAINT-GOBAIN CONSTRUCTION CHEMICALS

Saint-Gobain Construction Chemicals offers cement additives, concrete admixtures and specialty building materials, through the combined activities of Chryso and GCP. Its recent technologies for sustainable construction help reduce energy consumption, lower the carbon footprint of cements and concrete, and foster the circular economy. Leveraging its global manufacturing presence, Saint-Gobain Construction Chemicals serves its customers through local sites in over 40 countries, employing over 2,700 people.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press relations
CHRYSO
Daphnée DECAUDIN
Daphnee.decaudin@chryso.com
+33 6 19 07 64 74

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release

Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in

Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release

Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release

Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye